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Low-density lipoprotein receptor-mediated delivery of a
lipophilic daunorubicin derivative to B16 tumours in
mice using apolipoprotein E-enriched liposomes
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Division of Biopharmaceutics. Leidenr/Amsterdam Center for Drug Research. University of Leiden. PO Box 9503. 2300 RA Leiden. The Netherlands
Summary Many tumours express relatively high levels of low-density lipoprotein (LDL) receptors on their membranes. The LDL receptor is,
therefore, an attractive target for the selective delivery of antineoplastic drugs to tumour cells. We reported previously on the synthesis of
small apolipoprotein E (apoE)-containing liposomes that behave in vivo in a very similar way to native LDL. In this study, we examined the
interaction of this liposomal carrier with cultured B16 melanoma cells. Binding of apoE liposomes to the cells is saturable, with a maximum
binding of approximatety 90 000 particles per cell. Cross-competition studies indicated that apoE liposomes are bound by the LDL receptor.
Association of apoE liposomes to B16 cells is strictly Ca2- dependent. which forms additional evidence for a role of the LDL receptor. The
affinity of apoE liposomes for the LDL receptor on Bi 6 cells is 15-fold higher than that of LDL (0.77 vs 11.5 nm respectively). ApoE is essential
for the LDL receptor recognition because liposomes lacking apoE were, in competition studies, 20- to 50-fold less effective than apoE-
containing liposomes. We examined in Bi 6 tumour-bearing mice the tumour-localizing properties of apoE liposomes and the disposition of an
incorporated lipophilic derivative of daunorubicin (LAD). Tissue distribution studies showed that LAD-loaded apoE liposomes were taken up
and processed by the major LDL receptor-expressing organs (i.e. adrenals, liver and spleen). Of all other tissues, the tumour showed the
highest uptake. The distribution pattems of LAD-loaded apoE liposomes and native LDL in the tumour-bearing mice were very similar, which
supports the role of the LDL receptor in the disposition of the prodrug-loaded particles. The disposition of LAD followed the pattem of the
liposomal carrier. We conclude that apoE liposomes enable LDL receptor-mediated specific delivery of antineoplastic (pro)drugs to tumours,
and, therefore, constitute an attractive novel option for anti-tumour chemotherapy.
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Because of their rapid proliferation. tumour cells require large
amounts of cholesterol for the svnthesis of membranes. A varnetx
of tumour cells fulfil their need for cholesterol bv an increased
receptor-mediated uptake of the low-density lipoprotein (LDL).
For instance. malignant blood cells implicated in acute mveloid
leukaemia intemalize 3-100 times more LDL than normal cells
(Ho et al. 1978). In addition. tumours in brain. lung. colon. kidney
and tumours ofgr naecological origin have been sho%%n to express
high levels ofLDL receptors (Firestone. 1994). Because ofits high
expression in tumour cells. and because it is an internalizine
receptor. the LDL receptor is an attractive target for the selective
delisvery ofantineoplastic drugs to tumours.
LDL is a spherical particle of about 23 nm. with a core of
mainly cholesterol esters and a shell consisting of a monolayer of
phospholipids and some cholesterol. A large part of the surface of
LDL is covered by apolipoprotein B (apoB). which mediates
recognition of the particle by the LDL receptor (Broswn and
Goldstein. 1986) Various lipophilic antineoplastic (pro)drugs
have been incorporated into the lipid moiety of LDL. Most
drug-LDL complexes displayed. in cell culture. LDL receptor-
specific uptake of drug andlor improved tumour cell kill (Mosley
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Only a fe% in vivo studies with drug-LDL complexes has-e been
reported. Masquelier et al (1986) and Samadi-Baboli et al (1993)
showed that the LDL in drug-LDL complexes wvas cleared
normally. We examined earlier the in vivo fate ofboth the druc and
LDL in complexes that had been prepared by 'arious established
incorporation procedures (De Smidt and Van Berkel. 1990). These
complexes displayed LDL receptor-mediated uptake by cultured
cells. Howexer. we found that in vio the druc rapidly dissociated
from LDL. or that the complexes were taken up by mechanisms
independent ofthe LDL receptor. Probably. incorporation ofdrugs
into LDL causes subtle modifications in the structure of apoB.
which modifies the in vivo behaviour of LDL. Thus. the construc-
tion of a drug-LDL complex that has a satisfactorv in vivo behav-
iour constitutes a major problem for the application of LDL
receptor-mediated uptake. In addition. the limited axailability of
native LDL is a pharmaceutical limitation.
The preparation of LDL-resembling lipid particles from
commercially available lipids would facilitate a large-scale
production. These particles. how-ever. do need a specific marker to
ensure LDL-receptor recognition. As it is difficult to associate
delipidated apoB (514 kDa) with lipid particles in its correct
tertiary structure (Lundberg and Suominen. 1984: Lundberg et al.
1993). we explored the possibility of using apolipoprotein E as a
recognition marker. The 34-kDa glcoprotein apolipoprotein E
(apoE). present on triglyceride-rich lipoproteins like chy lomicrons
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and very low-densitv lipoprotein. represents a good alternative for
apoB. It is ahigh-affinity ligand forthe LDL receptor. ifassociated
with lipid particles (Innerarity and Mahley. 1978: Innerarity et al.
1979). The affinity ofparticles exposing minimally four copies of
apoE on their surface for the LDL receptor is even 15- to 25-fold
higher than that of native LDL. which is probably due to multi-
valent receptor binding (Pitas et al. 1979. 1980). An additional
advantage ofapoE is that it can be produced by recombinant DNA
technology.
We combined the advantages ofa synthetic lipid particle (large-
scale production) with those ofrecombinant apoE (as high-affinity
ligand for the LDL receptor) to construct a carrier suitable for the
specific delivery of drugs to tumours. Small liposomes (approxi-
mate size 29 nm) were prepared. which were provided with 5 or 6
apoE molecules perparticle (Rensen et al. 1997). These liposomes
were found to be stable in the circulation. Further. LDL receptor-
mediated uptake was demonstrated in vivo in rats with a chemi-
cally induced (by 17a-ethinyl oestradiol pretreatment) high-LDL
receptor expression on the liver. Uptake by the reticuloendothehal
system was negligible (Rensen et al. 1997). A lipophilic antineo-
plastic prodrug was synthesized. and incorporated in the lipo-
somes (Versluis et al. 1998). The prodrug. denoted LAD (Figure
1). consists of the anthracycline daunorubicin. which is coupled
via a lysosomally degradable tetrapeptide spacer (alanyl-
leucyl-alanyl-leucyl) to a cholesteryl oleate analogue [3cx-0-
(oleoyl)-503cholanic acid].
The aim of the present study was to investigate the tumour-
localizing properties of (LAD-loaded) apoE-enriched liposomes.
The B16 tumour-mouse model was used because the LDL
receptor expression on B16 cells has been well characterized
(Ponty et al. 1993: Versluis et al. 1996). We investigated the LDL
receptor-mediated interaction of apoE-enriched liposomes with
cultured B16 tumour cells. and evaluated the disposition of the
liposomal carrier and the liposome-associated prodrug in the
tumour tissue in vivo.
MATERIALS AND METHODS
Chemicals
Recombinant human apolipoprotein El (apoE). isolated from
Escherichia coli. was a generous gift from Dr T Vogel.
Biotechnology General. Rehovot Israel (Vogel et al. 1985). ApoE
was dissolved in phosphate-buffered saline (PBS: 10 lrOm sodium
phosphate buffer. pH 7.4. containing 0.15 M sodium chloride) at a
concentration of 2 mg, ml-'. and was stored under argon at -00C.
[l 2ca(N} Hjcholesteryl oleate ([- H]CO). [1 2a(N)-Hjcho-
lesteryl oleate ether ([ HlCO ether). cholesteryl [l-'4C]oleate
(['C]CO) and sodium 121 (canier free) were obtained from
Amersham International. Amersham. Buckinghamshire. UK.
[3H(G)]Daunorubicin was purchased from New England Nuclear
Research Products. Boston. MA. USA. [- H]LAD (purity >95%) was
syndtesized from [IH]daunorubicin as described previously by
Versluis et al (1998). Egg yolk phosphatidylcholne (EYPC. 98%)
was obtained from Fluka. Buchs. Switzerland Cholesteryl oleate
(CO. 97%) was fromJanssen Chimica. Beerse. Belgium. Cholesterol
oxidase. cholesterol esterase. peroxidase type H (200 U mg-1).
Precipath L. and a solution containing 50000 IUml-' penicillin
and 50 mg ml-' streptomycin were obtained from Boehringer
Mannheim. Mannheim. Germany. Dulbecco's modified Eagle
medium (DMEM) was from Gibco BRL Life Technologies.
Figure 1 Structure of LAD, a conjugate of3ao(oeoy)-50-dholanic acid
and alany-eucyl-abanydaeucyn-dauorubicn
Gaithersburg. MD. USA. Fetal calf serum was obtained from
Hyclone Laboratories. Logan. UT. USA. L-glutamine was from
Merck. Danrstadt Germany. A solution of 2.5% (w/v) trypsin in
Hanks' balanced salt solution without Ca'+ and Mg>+ was purchased
from Flow Laboratories. Irvine. UKT All other chemicals were of
analytical grade.
Preparation and apoE enrichment of (LAD)liposomes
Liposomes were prepared by sonication using a procedure
described previously by Rensen et al (1997). In short. EYPC and
CO (52 mg of total lipid at a ratio of 25:1) were hydrated in
11.4 ml of 10 mm tris-HCI buffer. pH 8.0. containing 0.1 MI potas-
sium chloride. The mixture was sonicated for 1 h under argon at an
18-im output. using a Soniprep 150 (MSE Scientific Instruments.
Crawley. W. Sussex. UK) equipped with a water bath to maintain
the temperature at 54°C. Liposomes were prepared with the
following additions: (a) 150gCi [ H]CO (for the in vitro experi-
ments): (b) 200jg unlabelled LAD. 60jCi ['H]CO ether. and
40gCi [I4C]CO (to study the in vivo processing ofthe liposomes):
or (c) 15 jiCi [ H]LAD (200jg) and 12 giCi ['4C]CO (for the
tissue distribution experiments). After sonication. the liposomes
were purified and concentrated by density-gradient ultracentrifu-
gation at 285 000 g for 18 h at 4°C. according to Redgrave et al
(1975). After centrifugation. the liposomes. visible as a narrow
opalescent layer at approximately three-quarters of the tube
height. were isolated by aspiration. When indicated. liposomes
were subsequently incubated with apoE. at an apoE:phospholipid
ratio of 1:10 (w/w). After 30 min at 37°C. the incubation mixture
was subjected to density-gradient ultracentrifugation as described
above. and apoE-containing liposomes were subsequently isolated
by aspiration. Finally, the (apoE) liposomes were dialysed against
PBS containing 1 ntm EDTA. Liposomes were stored at 200C
under argon and used within 7 days after preparation. in which
period no physicochemical changes could be detected.
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Characterization of lipsomes
The EYPC and CO contents ofthe purified liposomes were deter-
mined using enzymatic kits for phosphatidylcholine and esterified
cholesterol (Boehringer Mannheim, Mannheim, Germany) respec-
tively. Precipath L was used as standard. The incorporation of
[3H]LAD was assayed by measuring its radioactivity as described
below. Particle size and homogeneity were determined by photon
correlation spectroscopy at a temperature of 270C, using a
Malvem 4700c submicron particle analyser set at an angle of 900
between laser and detector (Malvern Instruments, Malvern,
Worcestershire, UK).
Isolation and radioiodination of LDL
Human LDL (density 1.024-1.063 g ml-') was isolated from the
serum of healthy fasted volunteers by density-gradient ultrwen-
trifugation according to Redgrave et al (1975). The LDL solution
was subsequently dialysed against PBS containing 1 mM EDTA,
and was sterilized by filtration through a0.22-jim filter (Millipore,
Molsheim, France). The concentration of the LDL solution was
determined by measuring apoB, according to the method ofLowry
et al (1951) with bovine serum albumin (BSA) as standard. For in
vitro experiments, LDL was labelled using the ['5l]iodine mono-
chloride method as described in detail by Bilheimer et al (1972).
For in vivo experiments, LDL was labelled with '1I-tyrammne
cellobiose ('-I-TC) as described previously (Versluis et al, 1996).
The specific radioactivity of radiolabelled LDL was 50-200
d.p.m. ng-' of apolipoprotein and less than 1% of the labelled
material was soluble in trichloroacetic acid.
Cufture of B16 Melanoma cells and of cells
for experiments
The B16 (wild type) melanma cell line was cultured at 37°C in a
humidified 5% carbon dioxide/air atmosphere in 500-cm2 flasks
(Costar), contining 20ml of DMEM supplemented with 10% (v/v)
heat-iactivated fetal calfserum. 2 mM L-glutamme, 50 IU ml' peni-
cilin and 50jg mL- streptomycu Cells were sbcured twice a
weekby detahiing the cells with ntypsin (0.25% solutio in Ca2- and
mg-depieted Hanks' buffer), followed by renewal of medium the
nextday. Protein content percell number wasdetermined according to
thenmetod ofLowryetal (1951) withBSA as sandard.
To perform experiments, B16 cells were plated in 22-mm-diam-
eter 12-well culture plates at a density of 20 000-40 000 cells per
well. Experiments were carried out 2 or 3 days later with subcon-
fluently grown cells. Before the experiments, the culture medium
was replaced by preincubation medium [medium with 1% (w/v)
BSA instead of fetal calf serum]. The cells were washed three
times with preincubation medium (for 10. 10 and 30 min), and
then cultured in this medium for a further 18 h. Experiments (see
below) were started, after two quick washes with preincubation
medium, by the addition of preincubation medium containing
radiolabelled ligands, either alone or with the indicated additions.
Binding of radioabelled apoE liposomes and LDL by
B16 cells in culture
To determine the binding of radiolabelled apoE liposomes and
LDL to B16cells, thecells were incubated with increasing concen-
trations ofthe radiolabelled ligand for3 hat4°C. Afterincubation,
the culture plates were placed on ice. The cells were washed five
times with ice-cold wash buffer (0.15 M sodium chloride, 2.5 mM
calcium chloride and 50 mM tris-HCI, pH 7.4) containing 0.2%
(w/v) BSA, followed by two washes with the same buffer without
BSA. The cells were then lysed with 1 ml of 0.1 N sodium
hydroxide and the amounts of protein and radioactivity in the
lysate were determined. The amount of cell protein was deter-
mined by the method ofLowry et al (1951) with BSA as standard.
Association and degradation of radiolabelled apoE
liposomes and LDL by B16 cells in culture
To determine association and degradation of radiolabelled apoE
liposomes and LDL by B16cells, the cells were incubated with the
radiolabelled ligands and the indicated additives for 3 h at 370C.
Afterthe incubation, theculture plates wereplacedon ice. Todeter-
mine degradation of ['5l]LDL, 0.5 ml of the incubation medium
was taken from the cells, and the amounts ofreleased degradation
products of ['2l51LDL were determined as described previously by
VanBerkeletal (1981). Thecell-associatedradioactivity wasdeter-
mined as described above forcell-bound radioactivity.
Detemination of in vivo fate of (LAD-loaded) apoE-
containing liposomes and LDL
Male C57/BL6 mice (10-15 weeks old) were used. The animals
were kept in compliance with the guidelines issued by the Dutch
authorities. The mice were fed with normal chow and had free
access to water. Mice were inoculated subcutaneously. both on the
left and the right flank of their back with 2.5 x 10-1 B16 cells
obtained from cell culture (inoculation was performed under
diethyl etheranaesthesia). Afterthe development ofsmall (<0.1 g)
tumours, the mice received an intravenous injection of radio-
labelled (LAD-loaded) apoE-containing liposomes. At 2, 4 or 8 h
after injection, the mice were anaesthetized with diethyl ether, and
a 0.4 ml blood sample was taken. The mice were subsequently
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Figure 3 Effects of unabelled (apoE-) liposomes and LDL on the
association (top panels) or degradation (bottom panels) of ['ILDL to B16
cels. B16 cells were incubated at 37°C with 20 nA (10 iggr') [SI]LDL in the
presence of the indicated concenratirons of unlabelled apoE4iposomes (0),
liposones devoid of apoE (3), or LDL (A). After 3 h of incubation, the
amount of cel-associated [15]LDL (panels A and B) and the amounts of
degradation products in Fe mediurn (panels C and D) were measured. The
anmunts of cell-associated and degraded ['Il]LDL are expressed as
pereages of the cotrol values obtained in the absence of compeator (378
+ 41, 436 125, 1703 _ 144, and 1558 479 ng ofapopoprotei/mg of cegl
protein for panels A, B, C and D, respectively). Values are means iividal
vanatons of two separate experiment
sacrificed by dislocation. Organs and tissues were removed by
dissection, wiped with atissue, weighed and the amount ofradioac-
tivity was determined. The radioactivity measured in organs and
tissues was corrected for the amount of serum radioactivity present
in the tissues after the time of sampling. The amounts of serum in
the organs and tissues were determined in separate experiments
using ['251]BSA. The tissue distribution of ['251TC-LDL was deter-
mined as described previously (Versluis et al, 1996).
Table 1 Effects of unlabelled (apoE)bposomes and LDL on the association
ofPH]C-abeled apoE liposomes by B16 cells. B16 cells were incubated at
37°C with 1.6 rw (-WCO-abeled apoE fiposomes (13 gg phospholip ml-')
in the presence of the indcated concentrations of cometior. After 3 h of
incubation, the aoKxnt of cell-associated radioactvity was measured. The
amount of celassociated radlolabeled apoE lposomes is expressed as
percentage of the values obtained in the absence of competitor. These
control values were 7.5 ± 0.2, 6.5 ± 0.3, and 6.7 ± 0.2 9g phospholipid m-yi
of cell protein for the apoE hposomes, the lposomes lacldng apoE and LDL
respecvely. Values are means ± iKdivKiual varitions of two separate
experiments
Associabti (% of control)
Compettor (rl) ApoE Ip m L e LDL
0 100±3 100_5 100_3
10 30±3 101±3 99±5
30 10±3 96+3 91±4
200 - - 62 ± 3
600 - - 39 ± 4
RESULTS
Interacton of apoE-enriched liposomes with cultured
B16 cells: bindingstudies
To study the binding ofapoE-enriched liposomes to B16 cells. the
cells were incubated at 4°C with increasing amounts of
[3H]cholesteryl oleate (['H]CO)-labelled apoE liposomes. After
3 h ofincubation, the binding ofthe radiolabelled liposomes to the
cells was detennined. The binding of the apoE liposomes to B16
cells was saturable (Figure 2). For comparison, the binding of
LDL to B16 cells is depicted in the insert. ApoE-enriched lipo-
somes bind to B16 cells with an affinity that is much higher than
the affinity of LDL for the LDL receptor on B16 cells. The Kd of
the binding of the apoE-enriched liposomal particles to B16 cells
was 15-fold lower than the Kd of the binding of LDL to cultured
B16 cells (0.77 ± 0.09 nm vs 11.5 ± 4.5 nM). The maximal binding
values (Ba) of apoE liposomes and LDL were 1.30 ± 0.02 jig of
phospholipid per mg cell protein and 206 ± 23 ng of apoB per mg
cell protein respectively. Assuming 1.I x 106 cells per mg of cell
protein, 1.2 x l10 LDL particles per mg of apoB. and 7.62 x 101
liposomes per mg ofphospholipid, the number ofbinding sites per
cell can be calculated for both ligands. The number of binding
sites for the apoE liposomes on B16 cells is somewhat lower
than the number of sites for LDL (90 000 ± 1400 sites per cell
vs 220 000 ± 25 000 sites per cell respectively).
Determination of radioactivity
3H-radioactivity and '-C-radioactivity were determined in a
Packard 1500 TriCarb liquid scintillation analyser. Cell-associated
3H radioactivity was counted after adding 10 ml of Ultima Gold
scintillation fluid to 800-pl samples of cell lysate. Radioactivity
(3H and "C) in serum, liver and other tissue samples was counted
after combustion in a Packard Tri-Carb 306 Sample Oxidizer
(recovery >97%). 14C radioactivity in the combusted samples was
measured in a Carbosorb E/Permafluor mixture (2:3 v/v), and 3H-
radioactivity was counted in Monophase S. '21-containing samples
were counted directly in a Minaxi Autogamma 5000. All instru-
ments and scintillation cocktails were from Packard Instrument
Company. Downers Grove. IL. USA.
Interaction of apoE-enriched liposornes with cultured
B16 cells: competition studies
To investigate the role of the LDL receptor in the interaction of
apoE-enriched liposomes with B16 cells, the ability of the lipo-
somes to compete with LDL for binding to the LDL receptor was
studied. B16 cells were incubated with 20 nm of [121]LDL
(approximately two times the Kd) in the presence of increasing
amounts ofunlabelled liposomes or LDL. The effects ofthe addi-
tions on the association of [211]LDL to B16 cells are shown in
Figure 3A and B, and the effects on the degradation of ['12]LDL
by the cells are depicted in Figure 3C and D. To examine the role
ofapoE, both apoE-containing liposomes and liposomes devoid of
apoE were used Both LDL and the liposomes were able to inhibit
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Table 2 Effect of Ca2- on the association of [3H]CO-labelled apoE
liposomes and [l25i]LDL by B16 cells. B16 cells were incubated at 37-C with
20 nM (10 ig mV) [t25i]LDL or 1.6 nm PHiCO-labelled apoE liposomes
(13 !±g phospholipid ml-). The medium contained the usual amount of Ca2-
(1.8 mm), or Ca2- was depleted by addiion of magnesium EGTA to an excess
of 2 mm. After 3 h of incubation. the amount of cell-associated radioactvity
was measured. The association is expressed as percentage of the
association at 1.8 mm Ca2- (364 ± 21 ng of apolipoprotein mg- of cell protein
for [-51]LDL and 10.7 t 0.2 ug of phospholipid mg- cell protein for
radiolabelled apoE liposomes). Values are means + s.d. of four expenments
Association (%o of control)
ApoE liposomes LDL
1.8 mv Ca- 100 - 2 100- 6
2 m. Magnesium EGTA excess 15 = 2 29 - 2
Figure 4 Serum clearance of apoE-containing LAD-liposomes in B16
tumour-bearing mice. Bi 6 tumour-bearing mice were intravenously injected
wih LAD-loaded apoE-liposomes, labelled with [31HlCO-ether (U) and
[14C]CO-ester (7), at a dose of 0.5 mg of phospholipid per mouse. Mice
were sacrificed at 2, 4 or 8 hours after injecton. and the radioactvity in the
serum was measured. Resufts are expressed as percentage of the injected
dose recovered in the serum. Values are means ± SD of 3-5 animals
the association and the degradation of ['2'IJLDL by B16 cells.
Association of [V2II]LDL was reduced by 50% in the presence of
50 nM of LDL. However. only 1.7 nm apoE-enriched liposomes
was sufficient to obtain a similar competition. Compared with the
apoE liposomes. liposomes lacking apoE were approximately 20-
fold less effective in competing with [2'11]LDL for association by
B16 cells. The degradation of ['2'1]LDL was inhibited even more
efficiently by apoE-enriched liposomes: 50%7 inhibition was
observed after addition of 0.8 nm of apoE liposomes. LDL and
liposomes without apoE were less effective.
Table 1 summarizes the results of a competition study in which
B16 cells were incubated with 1.6 nm of radioactively labelled
apoE-enriched liposomes (approximately twice the K.) in the
presence of increasing amounts of unlabelled apoE-enriched
liposomes. Iiposomes or LDL. The results resemble the above-
mentioned findings with iodinated LDL as radiolabelled substrate.
LDL and unlabelled apoE-enriched liposomes were both able
to inhibit the association of the radiolabelled apoE-enriched
Figure 5 Uptake of apoE-enriched LAD-liposomes by liver. adrenals.
spleen and tumour in B16 tumour-bearing mice. B16 tumour-bearing mice
were intravenously injected with LAD-loaded apoE-liposomes. labelled with
[3H1CO-ether (-) and ['4CCO-ester (-). at a dose of 0.5 mg of phospholipid
per mouse. Mice were sacrificed at 2. 4 or 8 hours after injection. and the
radioactity in the liver. adrenals. spleen and tumour was measured. The
results are expressed as the percentage of the injected dose that was
recovered per gram of tissue and are means SD of 3-5 animals
liposomes. How-ex er. it took 600 nrx ofLDL to displace 60%- ofthe
associated apoE-enriched liposomes. W-hereas onlv 30 nm of unla-
belled apoE-enriched liposomes sufficed to inhibit the association
of the labelled apoE-enriched liposomes bv 90'c. The addition of
an equal amount of liposomes without apoE had no significant
effect on the association of the labelled apoE-enriched liposomes.
We conclude from the cross-competition studies that the interac-
tion of apoE-enniched liposomes Awith B16 cells is LDL-receptor
mediated. Our results further indicate that the presence of apoE is
crucial for the interaction ofthe liposomes %vith B 16 cells.
Interaction of apoE-enriched liposomes with cultured
B16 cells: Ca2--depletion studies
The binding ofLDL to the 'classical' LDL receptor is strictly Ca'
dependent (Goldstein and Brown. 1974). We showed recentlI that
the interaction of LDL with B16 cells is also strongly Ca'+ depen-
dent (Versluis et al. 1996). Table 2 demonstrates that the associa-
tion of apoE-enriched liposomes wvith B16 cells is. like LDL.
stronglv diminished by depletion of Ca'-. w-hich indicates that the
LDL receptor is inv-ohed in the interaction of apoE-enriched lipo-
somes Aith B16 cells.
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Figure 6 Tissue distribution of LAD-loaded apoE-liposomes. Bi 6 tumour-
bearing mice were intravenously injected with LAD4oaded apoE-liposomes.
labelled with either [3H]CO-ether (-) or [H]LAD (7). at a dose of 0.5 mg of
phospholipid per mouse. Eight hours after injctkon, a 0.4 ml blood sample
was taken and the mice were sacrificed. Radioactivity was measured in
the indicated organs and tissues. Results are expressed as the percentage
of the injected dose that was recovered per gram of tissue, and are
means + SD of 2 or 5 animals ([3H]LAD or [3H]CO-ether abe, respectively)
Disposition of apoE-enriched liposomes and liposome-
associated LAD in mice bearing B16 tumours
To MN-estigate in xixo the tumour-localizing properties of apoE-
enriched liposomes and their ability to deli-er drugrs to tumours.
W e incorporated LAD. a lipophilic prodrug ofthe anti-tumour drug
daunorubicin. into the liposomes. Subsequentl. we examined the
fate of the apoE liposomes and the prodrug in mice bearing a B16
tumour.
Initiallx. se studied the processing of the apoE-enriched LAD
liposomes. The liposomes w-ere labelled with both a biodegradable
label (['4C]cholesteryI oleate ester) and a non-degradable label
(['H]cholesterxl oleate ether). The radiolabelled liposomes A-ere
injected into the tumour-beafina mice. and the serum clearance of
both labels and their accumulation in sex-eral LDL receptor-
expressing organs (i.e. li-er. adrenals and spleen) and in tumour
tissue were monitored. The serum clearance. presented in Figure 4.
was similar for both labels. The amount ofnon-degradable label in
lix-er. adrenals and spleen. which represents the absolute uptake of
the apoE-enriched LAD liposomes. increased xwith the circulation
time (Figrure 5). The amount of degradable label in these tissues.
howex-er. A-as much lower. This indicates that the LAD-loaded
apoE liposomes are internalized and processed in tissues. followed
bx excretion of the radiolabelled degradation products. ApoE-
enriched LAD liposomes also accumulated in the tumour.
How-exer. no sirnificant amounts of the biodegradable label A-ere
excreted from the tumour. not ex-en after 8 h.
To inxestigate in x-ix-o the tumour uptake of a liposome-
associated drug. ['HILAD A-as incorporated into liposomes. The
drug-carrier complex was proxvided with apoE and injected into
B16 tumour-bearinnc mice. Figure 6 shows the distribution of
['H]LAD radioactixitx oxer tissues. w-hich A-as determined 8 h
Figure 7 Tissue distribution of [3HICO-ether labelled LAD-loaded apoE-
liposomes and [8251]TC-LDL in B16 tumour-beanng mice. B16 tumour-bearing
mice were intravenously injected with [30CO-ether labelled LAD-loaded
apoE-liposomes (U; 0.5 mg of phospholipid per mouse) or with ['l51]tyramine
cellobiose-labelled LDL (7: 40 gg of apolipoprotein per mouse). Mice were
sacrficed 24 h (LDL injection) or 8 h (liposomes injecton) later, and
radioactvity was measured in the indicated organs and tissues. Results are
expressed as the percentage of the injected dose that was recovered per
gram of tissue, and are means ± SD of 3 or 5 animals (['alI1TC-LDL or
[3H]CO-ether liposomes, respectively)
later. To monitor the fate of the liposomal carrier. mice in a sepa-
rate experiment were injected with apoE-enriched LAD liposomes
that had been radioactivelv labelled with the non-degradable lipid
[ H]cholesterxl oleate ether (represents total uptake ofliposomes:
Figure 6). Both distinctlI labelled preparations behaxved similarly
in ixvo. asjudged from the disposition of simultaneouslx incorpo-
rated ['4C]cholestervl oleate ester (not shown . Eight hours after
injection. the recovered amounts of LAD and apoE liposomes in
serum were very similar (27%e ± 2% and 30%7c ± 3%- ofthe injected
dose respectixvelv). As estimated from the accumulation of the
radiolabelled cholesterxl oleate ether. the lixver. adrenals and the
spleen showed the highest uptake of apoE-enniched liposomes
(Figure 6). The tumour show-ed the highest uptake of all other
organs. The distribution of radioacti'vitx after injection of
['H]LAD-labelled liposomes followxed the same pattern. Howxex er.
the amounts ofrecoxvered radioactixvity ere lower. wxhich points to
metabolism ofthe radiolabelled prodrug.
Figure 7 compares the tissue uptake of the apoE-enriched LAD
liposomal carrier with that of natixe LDL. Both carriers wxere
labelled with a non-degradable label. The liposomes w-ere labelled
with [ H]CO ether and LDL with [1'il]tyramine cellobiose (TC:
Pittman et al. 19831. The distributions of the labelled liposomes
and LDL were determined after 8 h (70%c ±3 %}ck ofthe dose cleared
from the serum) and 24 h (85%7e ± 3%c of the dose cleared) respec-
tixelv. It should be noted that after uptake of ['-l]TC-labelled LDL
bv the lix-er. part of the ['-'1]TC radiolabel is excreted x-ia the bile
into the intestines (Kleinherenbrink-Stins et al. 1990). Therefore.
the amount of TC label in the intestines should be added to the
amount in the lixer. Taking this ['"'I]TC transfer into considera-
tion. the uptake pattern of the LAD-loaded apoE-enriched
British Joumal of Cancer (1998) 78(12). 1607-1614
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liposomes by the organs and the tissues shows a striking similarity
with that of LDL. which strongly suggests the involvement of the
LDL receptor in the uptake of LAD-loaded apoE-enriched
liposomes.
DISCUSSION
We recently synthesized small apoE-containing liposomes. with the
aim of using these particles for the selective delivery of antineo-
plastic agents to tumours via the LDL receptor. The apoE liposomes
behaved in vivo similarly to native LDL (i.e. no significant uptake
by the reticuloendothelial system and metabolic fate dependent on
the level of LDL-receptor expression: Rensen et al. 1997). We
ftherincorporated LAD. alipophilic prodrug, ofdaunorubicin. into
these liposomes (approximately ten prodrug molecules per particle:
Versluis et al. 1998). In the present study. we investigated the inter-
action of apoE-containing liposomes with cultured B16 melanoma
cells, and we studied the tumour-localizing properties of LAD-
loaded apoE-liposomes in the B16 tumour-mouse model.
The binding of apoE liposomes to cultured B16 cells was
saturable, indicating receptor-mediated binding. Cross-competi-
tion studies with LDL indicate that apoE liposomes are specifi-
cally bound by LDL receptors on B16 cells. Further evidence for
implication ofLDL receptors comes from the finding that associa-
tion of apoE liposomes with B16 cells is Ca'+ dependent. a clas-
sical characteristic of the LDL receptor (Goldstein and Brown.
1974). The essential role of apoE for the recognition of the lipo-
somes by the LDL receptor became evident from the finding that
liposomes lacking apoE are far less effective in competing for
receptor binding. ApoE liposomes bind to the LDL receptor with a
15-fold higher affinity (Kd 0.77 nM) than LDL (Kd 11.5 nm). The
number of binding sites for apoE liposomes is. however, two- to
2.5-fold lower than that for LDL (90 000 versus 220 000). These
results are in agreement with the findings ofPitas et al (1980). who
showed that lipid vesicles provided with increasing numbers of
apoE molecules displayed an increasing affinity for the LDL
receptor. The maximum affinity. which was 25-fold higher than
that of LDL. was reached when at least four apoE molecules were
present per particle. At this point. the maximal binding capacity
was decreased fourfold. indicating multivalent binding of the
apoE-containing particles to LDL receptors.
The tumour-localizing properties of the apoE liposomes were
studied by administering LAD-loaded apoE-liposomes to B16
tumour-bearing mice. To study processing. the liposomes were
double-labelled with a non-degradable lipid label (represents total
amount taken up) and a biodegradable label. The latter can be
metabolized and excreted. and gives an indication of the
processing of the particles. We found that the particles are not
processed in the circulation, but were taken up and rapidly
processed by the three organs with a high expression of the LDL
receptor (i.e. liver. adrenals and spleen). Thus. the prodrug-loaded
liposomes are. like native LDL. intemalized and processed. Of all
other organs. the tumour showed the highest uptake. However. we
detected no significant difference in accumulation of the labels in
the tumour. This finding does not necessarily mean that the lipo-
somes are not processed by the tumour. The liver and adrenals use
cholesterol for the synthesis ofsecretion products (bile salts. corti-
costeroid hormones). Tumours. however. use the cholesterol to
synthesize cellular components that remain cell-associated.
Further. earlier results indicate that LDL is processed by the B16
tumour inoculated in mice. albeit at a somewhat lower rate than in
liver and adrenals (Versluis et al. 1996). The tissue distribution of
LAD-loaded apoE-liposomes is very similar to that ofnative LDL.
which further supports the involvement ofthe LDL receptor in the
uptake ofLAD-loaded apoE liposomes.
The ability ofthe apoE liposomes to deliver LAD to the tumour
was studied by injecting [3H]LAD-loaded apoE liposomes. The
serum clearance of the radiolabelled prodrug was similar to the
serum clearance ofthe radioactivity after injection ofLAD-loaded
[3H]CO-labelled apoE liposomes. indicating a concomitant clear-
ance and uptake of drug and carrier. The recovery of LAD in the
tissues was much lower than that of the non-degradable liposomal
label. which points to processing of the prodrug. This suggests
that. as anticipated. daunorubicin is released from the tetrapeptide
spacer and is further metabolized. Assuming that all incorporated
LAD is delivered to the tumour. and that tumour cells constitute
10% of the tumour weight (Murray and Carmichael. 1995). it can
be calculated that approximately 0.2 tmol of LAD can be deliv-
ered per litre of B16 cell volume at the present dosing. The effec-
tive intracellular anthracycline concentration. which is in the JiM
range (Speth et al. 1988). should easily be reached by higher and
more frequent dosing.
Uptake of the prodrug-loaded liposomes by liver. spleen and
adrenals is higher than the uptake by the tumour. If a therapeutic
dose is to be targeted to the tumour. precautions are necessary to
protect these organs from irreversible tissue damage. Expression of
LDL receptors in the liver can be decreased by a diet enriched in
cholesterol andtriglycerides rich in saturatedfatty acids (Angelin et
al. 1983: Dietschy et al. 1993: Packard et al. 1983). The expression
of LDL receptors in the spleen and adrenals can be significantly
reduced by the administration of bile salts and corticosteroids
respectively (Hynds et al, 1984: Isaacsohn et al. 1986).
In conclusion. apoE liposomes. prepared from commercially
available lipids and recombinant apoE. can be used as carriers for
LDL receptor-mediated delivery ofdrugs to tumours. The particles
have a much higher affinity for the LDL receptor than native LDL.
which affords a competitive advantage. The liposomes have the
capacity to incorporate lipophilic anti-tumour (pro)drugs in the
phospholipid bilayer and water-soluble drugs in the aqueous core.
which provides numerous possibilities to further develop the drug-
disposing properties of the apoE-enriched liposomes. ApoE-
enriched liposomes are. thus. a new option and stimulus for the
application of a LDL receptor-mediated tumour therapy.
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